We are live on ! Find out more
DRUG

Bright Minds Biosciences

9 hedge funds and large institutions have $2.93M invested in Bright Minds Biosciences in 2021 Q4 according to their latest regulatory filings, with 9 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

1.54% more ownership

Funds ownership: 0%1.54% (+1.5%)

Holders
9
Holders Change
+9
Holders Change %
% of All Funds
0.14%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
9
Increased
Reduced
Closed
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
O
1
OrbiMed
New York
$2.13M +$2.94M +132,120 New
IC
2
Ikarian Capital
Texas
$317K +$445K +20,000 New
AI
3
AdvisorShares Investments
Maryland
$304K +$427K +19,188 New
QFA
4
Quattro Financial Advisors
Texas
$67K +$94.1K +4,230 New
CCA
5
Checchi Capital Advisers
California
$45K +$62.9K +2,828 New
BFM
6
Boothbay Fund Management
New York
$35K +$49.1K +2,208 New
BlackRock
7
BlackRock
New York
$20K +$27.5K +1,234 New
UBS Group
8
UBS Group
Switzerland
$5K +$6.94K +312 New
APC
9
Aspire Private Capital
North Carolina
$2K +$2.23K +100 New

DRUG Hedge Fund Activity: Q4 2021 in Review

9 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Bright Minds Biosciences (DRUG) for Q4 2021, worth a combined $2.93M.

Buyers outnumbered sellers: 9 funds opened new DRUG positions and 0 closed out — a net gain of 9 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was OrbiMed, opening a new position worth an estimated $2.94M.

  • 9 institutional investors held Bright Minds Biosciences (DRUG) as of Q4 2021, up from 0 in Q3 2021.
  • Funds reported $2.93M of Bright Minds Biosciences stock for Q4 2021.
  • 9 funds opened new Bright Minds Biosciences positions in Q4 2021 and 0 closed out, a net change of +9 holders.
  • The largest Bright Minds Biosciences buyer in Q4 2021 was OrbiMed, an estimated $2.94M added.

Based on aggregated 13F filings for Q4 2021.